ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNPHY Santen Pharmaceutical Company (PK)

11.20
-0.18 (-1.58%)
Last Updated: 19:51:26
Delayed by 15 minutes
Name Symbol Market Type
Santen Pharmaceutical Company (PK) USOTC:SNPHY OTCMarkets Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.18 -1.58% 11.20 11.17 11.23 12.15 10.32 10.7825 3,182 19:51:26

Aerie Completes Enrollment of Phase 3 Glaucoma Study in Japan

17/06/2021 12:10pm

Dow Jones News


Santen Pharmaceutical (PK) (USOTC:SNPHY)
Historical Stock Chart


From Dec 2019 to Dec 2024

Click Here for more Santen Pharmaceutical (PK) Charts.

By Matt Grossman

 

Aerie Pharmaceuticals Inc. has completed patient enrollment of a Phase 3 study in Japan testing its netarsudil ophthalmic solution as a treatment for glaucoma or ocular hypertension, Aerie said Thursday.

The Durham, N.C.-based pharmaceutical company said that the study has enrolled 245 patients. The patients have received treatment either with netarsudil or with ripasudil, another solution that is approved in Japan. The trial is expected to be completed by the end of 2021, Aerie said.

Netarsudil has already been approved to treat some eye conditions in the U.S. The Japanese study is being co-funded with Santen Pharmaceutical Co., which has an exclusive collaboration and license agreement with Aerie for netarsudil in Japan and other Asian countries.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

June 17, 2021 06:55 ET (10:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Santen Pharmaceutical (PK) Chart

1 Year Santen Pharmaceutical (PK) Chart

1 Month Santen Pharmaceutical (PK) Chart

1 Month Santen Pharmaceutical (PK) Chart

Your Recent History

Delayed Upgrade Clock